Given the high burden of HCC in H/L populations and the limited molecular characterization of this disease [36] in this group, this study—building on prior health disparity research in other cancers [37,38,39]—aims to comprehensively analyze genomic alterations in the RTK/RAS, TGF-beta, WNT, PI3K, and TP53 pathways in HCC. This evidence concerns the gene TP53 and hepatocellular carcinoma.